

## AMENDMENTS

### In the Title:

Please delete the Title and replace it with --Conjugates of T Cell Epitope Deficient Immunogen Analogs for Humoral Anergy and Chemically Defined Non-Polymeric Valency Platform Molecules--.

### In the Cross Reference to Related Applications:

Please delete the entire paragraph on page 1 under the heading "Cross Reference to Related Applications," and substitute therefore the following paragraph:

--This application is a continuation of U.S. Patent Application Serial No. 08/769,041, filed December 18, 1996, which is a divisional of U.S. Patent Application Serial No. 08/453,254, filed May 30, 1995, now U.S. Patent No. 5,606,047, which is a continuation of U.S. Patent Application Serial No. 08/152,506, filed November 15, 1993, now U.S. Patent No. 5,552,391, which is a continuation-in-part of U.S. Patent Application Serial No. 07/914,869 filed July 15, 1992, now U.S. Patent No. 5,276,013; and a continuation-in-part of U.S. Patent Application Serial No. 08/118,055, filed September 8, 1993, U.S. Patent No. 6,060,056. The disclosures of each of these parent applications and patents are incorporated herein by reference.--

### In the Specification:

On page 2, line 31, delete "Saski" and insert --Sasaki--;

line 33, delete "(987)" and insert --(1987)--.

On page 3, line 14, delete "fluctuates" and insert --fluctuate--;

line 24, delete "chemical" and insert --synthetic--;

line 29, delete "chemical" and insert --synthetic--.

On page 4, line 30, delete "polyglycol" and insert --polyether--.

On page 5, line 1, delete " $C(CH_2OCH_2CH_2)_s(OH)_{4-s}$ " and insert  
-- $C(CH_2OCH_2CH_2)_s(CH_2OH)_{4-s}$ --;

line 18, delete " $S(=O)CR^B=CR^B_2$ " and replace it with  
-- $S(=O)_2CR^B=CR^B_2$ --;

line 24, delete " $-C(=O)CHCHC(=O)-$ " and insert  
--- $C(=O)CH=CHC(=O)-$ ;

line 25, delete " $S(=O)CR^B=CR^B_2$ " and replace it with  
-- $S(=O)_2CR^B=CR^B_2$ --.

On page 10, line 15, delete "chemical" and insert --synthetic--.

On page 12, line 20, delete " $C(CH_2OCH_2CH_2)_s(OH)_{4-s}$ " and insert  
-- $C(CH_2OCH_2CH_2)_s(CH_2OH)_{4-s}$ --.

On page 13, lines 1 and 10, delete " $-C(=O)CHCHC(=O)-$ " and insert  $\pi E$   
--- $C(=O)CH=CHC(=O)-$ .

On page 15, line 15, after "shown," insert --or with saline--.

On page 17, line 33, after "itself" insert --or when administered as the platform portion of  
a conjugate--.

On page 19, line 11, after "antibody" insert --and or apoptosis--.

On page 20, line 13, delete "chemical" and insert --synthetic--;

line 17, delete "chemical" and insert --synthetic--.

On page 25, line 10, delete "phosphormidate" and insert --phosphoramidite--.  $\pi E$

On page 26, line 12, delete " $\alpha$ -sperm" and insert --sperm--.

On page 27, line 6, delete "eptiopes" and insert --epitopes--.

On page 29, lines 8 and 9, delete "is reacted in the presence of  $NaCNBH_3$  with amino  
platforms to form conjugates" and insert --are reacted with amino platforms in the presence of  
 $NaCNBH_3$  to form conjugates--.

line 11, delete "glycol-lipids" and insert --glycolipids--.

On page 30, line 23, delete "dimethyl formamide" and insert --dimethylformamide--;

line 28, delete "N-methylmorpholine oxide" and insert

--N-methylmorpholine-N-oxide--.

On page 86, line 9, delete "Hydroxysuccinimidyl" and insert --Succinimidyl";

On page 95, line 18, delete "μM" and insert --μmol--.

line 19, delete "μM" and insert --μmol--.

On page 99, line 3, after "synthesis" insert --which incorporates the elements of an acyclic triol moiety (ACT)";

line 7, delete "d-[DMTr-(bzCp(CE)bzA)<sub>25</sub>]" and insert --d-[DMTr-(BzCp(CE)BzA)<sub>25</sub>]--.

On page 100, line 24, after "polynucleotide" insert --,PN-KLH--.

On page 103, line 18, before "5' " insert --Tr- --;

line 23, before "5' " insert --Tr- --.

On page 104, line 30, after "nm" insert --,assumed--".

On page 105, line 20, before "5' " insert --Tr- --;

line 23, before "5' " insert --Tr- --.

On page 106, line 23, before "5' " insert --Tr- --;

line 26, before "5' " insert --Tr- --.

On page 119, Table 6, please delete the last entry "8" in the column entitled "Peptide Conjugated" and replace with --9--.

In the claims:

Please cancel claims 2-21 without prejudice or disclaimer.

Please add new claims 22-51 as follows.